U.S. drugmaker Pfizer's new $11 billion share repurchase plan is deflating expectations that it will make a new bid for AstraZeneca.» Read More
A new Clovis cancer drug has been associated with high blood sugar and linked to diabetes in trial. CEO Patrick J. Mahaffy, Clovis Oncology, weighs in on the recent report.
Valeant and ally Pershing Square prepared to take its $53.8 billion takeover bid for Allergan directly to shareholders.
Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.
As the ASCO meeting gets underway in Chicago, here's a look at where we stand in the fight against cancer.
A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?
What's next for Pfizer, now that its bid for AstraZeneca has been laid to rest, at least temporarily. Analysts weigh in with their views.
Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.
As debate rages over costly drugs like Gilead's Solvadi, patients caution: Treatment is priceless.
CNBC biotech and pharmaceutical reporter Meg Tirrell discusses what happens on the flip-side of high health-care costs—when antibiotic costs become too low and stifle development.
Express Scripts' Steve Miller has embarked on a drug pricing crusade, with the goal of bringing down costs.
The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch with total spending last year rising 3.2 percent, to $329.2 billion.
Instead of criticizing foreign deals, we should be talking about corporate-tax reform to bring business—and jobs—back to the US, says Jake Novak.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.
AstraZeneca shares fall 13 percent after it rejects a final bid from Pfizer, calling the offer inadequate and presenting significant risks.
Ahead of the year's biggest event in cancer research, ASCO, research revealed AstraZeneca's cancer drug may have competition from Clovis Oncology.
The war of words over Pfizer’s attempts to take over AstraZeneca has escalated, with one politician invoking rape to describe the U.S. giant’s bids.
Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.
Get the best of CNBC in your inbox